Thank you to our investors for supporting Valinor in our mission to use AI to transform clinical trials, which are the core bottleneck to drug development.
The work ahead is clear: partner with drug developers to bring better medicines to market faster by making every clinical trial smarter, more targeted, and more likely to succeed for patients.
Now back to work!
Valinor is building momentum with a $13 million funding round to increase clinical trial success through our ML platform.
Thank you to our investors @CRV, @HarpoonVentures, @AminoCollective, and @Pelion_VP for backing our vision to help shape the future of faster, more efficient drug development.
This investment will fuel the expansion of our proprietary patient-derived datasets and grow our San Francisco-based team.
Our multimodal ML models are trained on matched multi-omic and clinical outcome datasets to better predict patient response — helping drug developers identify responders earlier, design smarter trials, and uncover new insights from real-world biology.
If you are working on clinical drug programs and want to learn more about Valinor's predictive ML models for patient response please reach out!
As part of Josh's launch, I got to sit down with him and unpack how he's automating clinical trials.
When 90% of trials fail, something is clearly wrong with the way we synthesize new drugs to tackle diseases like cancer and Alzheimer's.
Valinor is changing that.
Thomas Edison once said:
“Our greatest weakness lies in giving up. The most certain way to succeed is always to try just one more time.”
@VancityReynolds this is me trying one more time. Join me on the show and let’s have an incredible discussion.
If you retweet this and Ryan agrees to the show, I will choose one person who retweeted and give them $25,000. 🤩